Opportunities
Search

The Division of Mathematical Sciences (DMS)in the Directorate for Mathematical and Physical Sciences (MPS) at the National Science Foundation (NSF)and the National Institute of General Medical Sciences (NIGMS) at the National Institutes of Health (NIH)plan to support fundamental research in mathematics and statistics necessary to answer questions in the biological and biomedical sciences. Both agencies recognize the need to promote research at the interface between mathematical and life sciences. This program is designed to encourage new collaborations, as well as to support innovative activities by existing teams. The joint DMS/NIGMS initiative offers two submission tracks: Track 1 - for projects with a total budget of up to $600,000 for an award duration of 3 years, and Track 2 - for projects with a total budget of up to $1,200,000 for an award duration of 3-4 years.

This Notice of Funding Opportunity (NOFO) is one of three NOFOs for the National Cancer Institute (NCI) Community Oncology Research Program (NCORP). NCORP is designed to enhance generalizability and dissemination of clinical trial and other human subject research study results through accrual in a variety of community settings. The purpose of NCORP is to engage cancer patient populations, those at risk of cancer, and organizations in rigorous studies focused on cancer control, prevention, treatment and care delivery.NCORP is a community-based research network that:Designs and conducts clinical trials and other human subject studies for adults and children in cancer control, prevention, screening, and care delivery, as well as quality-of-life studies embedded within treatment trials;Enhances patient and provider access to treatment and imaging trials conducted under the National Clinical Trials Network (NCTN)NCORP will support the following components that will be individually awarded through the respective Request for Applications (RFAs) indicated below:NCORP Research Bases (UG1 Clinical Trials Required);NCORP Community Sites (UG1 Clinical Trials Not Allowed)(covered by this NOFO); andNCORP Academic Community Sites (UG1 Clinical Trials Not Allowed).The NCORP Community Sites is a healthcare system, a consortium of healthcare systems, or a consortia of community hospitals and/or oncology practices, public hospitals, and/or health care centers that can enhance the representativeness of participants accrued to cancer control, prevention, treatment and care delivery clinical tri...

This Notice of Funding Opportunity (NOFO) is one of three NOFOs for the National Cancer Institute (NCI) Community Oncology Research Program (NCORP). NCORP is designed to enhance generalizability and dissemination of clinical trial and other human subject research study results through accrual in a variety of community settings. The purpose of NCORP is to engage cancer patient populations, those at risk of cancer, and organizations in rigorous studies focused on cancer control, prevention, treatment and care delivery.NCORP is a community-based research network that:Designs and conducts clinical trials and other human subject studies for adults and children in cancer control, prevention, screening, and care delivery, as well as quality-of-life studies embedded within treatment trials;Enhances patient and provider access to treatment and imaging trials conducted under the National Clinical Trials Network (NCTN);NCORP will support the following components that will be individually awarded through the respective Request for Applications (RFAs) indicated below:NCORP Research Bases (UG1 Clinical Trials Required)(covered by this NOFO);NCORP Community Sites (UG1 Clinical Trials Not Allowed); andNCORP Academic Community Sites (UG1 Clinical Trials Not Allowed).NCORP Research Bases will serve as the program's research hubs and are expected to:Provide an established organizational structure, with scientific and statistical leadership for developing, implementing, and analyzing multi-institutional cancer control, prevention, and care delivery (CCP&CD) clinical research, as well as qualit...

This Notice of Funding Opportunity (NOFO) is one of three NOFOs for the National Cancer Institute (NCI) Community Oncology Research Program (NCORP). NCORP is designed to enhance generalizability and dissemination of clinical trial and other human subject research study results through accrual in a variety of community settings. The purpose of NCORP is to engage cancer patient populations, those at risk of cancer, and organizations in rigorous studies focused on cancer control, prevention, treatment and care delivery.NCORP is a community-based research network that:Designs and conducts clinical trials and other human subject studies for adults and children in cancer control, prevention, screening, and care delivery, as well as quality-of-life studies embedded within treatment trials;Enhances patient and provider access to treatment and imaging trials conducted under the National Clinical Trials Network (NCTN);NCORP will support the following components that will be individually awarded through the respective Request for Applications (RFAs) indicated below:NCORP Research Bases (UG1 Clinical Trials Required);NCORP Community Sites (UG1 Clinical Trials Not Allowed); andNCORP Academic Community Sites (UG1 Clinical Trials Not Allowed)(covered by this NOFO)NCORP Academic Community Sites are a consortium led by an academic center with a network of community hospitals and/or oncology practices, public hospitals, and/ or other healthcare centers that serve a patient population that can enhance the representativeness of participants accrued to cancer control, prevention, treatment and....

Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports impactful, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with Duchenne muscular dystrophy (DMD) in the near term. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale. The DMDRP strongly encourages research projects investigating therapies designed to demonstrate efficacy cross the life span, including infants, toddlers and nonambulatory individuals.Distinctive Features: The FY26 DMDRP IDA mechanism offers three eligibility career categories:• The Established Investigator category is for independent investigators at all academic levels, or equivalent• The New Investigator – Early-Stage category is for independent investigators early in their careers (i.e., within 10 years of their first faculty appointment or equivalent). Applicants in this category will be reviewed separately from Established Investigators.• The New Investigator – Transitioning category is for independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy who are seeking to transition to a career in DMD, thereby bringing their expertise to the field. Applicants in this category will be reviewed separately from Establi...

Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Clinical/Translational Research Award (CTRA) supports advanced translational research to accelerate promising ideas in Duchenne muscular dystrophy (DMD) research toward clinical applications. Research must address at least one of the FY26 CTRA Focus Areas. Research projects investigating therapies that will be efficacious across the life span are strongly encouraged.Distinctive Features: The FY26 CTRA offers two funding levels:• Funding Level 1 to support smaller, less complex preclinical and/or clinical research.• Funding Level 2 to support larger, more complex preclinical and/or clinical research.The FY26 CTRA also offers a Partnering PI Option (PPIO) to support meaningful and productive partnerships between two investigators collaborating on the proposed research project. The PPIO has two eligibility categories:• Early-Career Partnering PI category for an independent, early-career investigator within 10 years of their first faculty appointment (or equivalent) by the time of application submission.• Established Interdisciplinary Partnering PI for independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy, seeking to transition to a career in DMD, thereby bringing their expertise to the field.Preliminary data are required for all applications. Pilot clinical trials and clinical trial readiness studies to better inform development of drugs, devices, and other interventions are allowed.

The Competitive State Wildlife Grant (C-SWG) Program provides Federal cost-sharing awards that help the State, Territory, and District of Columbia fish and wildlife agencies and their regional associations design and implement proactive conservation programs benefiting wildlife and their habitats. Proactive approaches to conservation help these recipients and their conservation partners avoid more prescriptive Federal regulatory requirements associated with species listing under the Endangered Species Act.The C-SWG Program prioritizes implementation of conservation actions described in the State and Territory Wildlife Action Plans (Plans). Projects must benefit one or more species of greatest conservation need or their habitats as identified in the Plans.This announcement provides complete information on preparing and submitting an application, including details on award tiers, partnership requirements, and the maximum Federal share of an award. The award tiers and related requirements are intended to encourage partnerships dedicated to cross-jurisdictional conservation efforts supporting landscape-scale conservation.

Buyer: Métropole européenne de Lille | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-09-18

Buyer: European Centre for Medium Range Weather Forecasts (ECMWF) | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-09-18

Buyer: SADEV 94 | Notice type: cn-standard | Procedure: neg-w-call | Contract: services | Deadline: 2026-09-18

Buyer: Rennes Métropole | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-09-18

Buyer: Région Ile de France | Notice type: cn-standard | Procedure: open | Contract: works | Deadline: 2026-09-18

Buyer: Regione Toscana | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-09-18

Buyer: Opéra national de Paris | Notice type: cn-standard | Procedure: comp-dial | Contract: services | Deadline: 2026-09-18

Buyer: Université Toulouse Jean Jaurès | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-09-18

Buyer: Partenord Le groupe | Notice type: cn-standard | Procedure: open | Contract: works | Deadline: 2026-09-18

Buyer: Communauté de Communes du Lautrécois Pays D'Agout | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-09-18

Buyer: Université Polytechnique Hauts de France | Notice type: cn-standard | Procedure: open | Contract: works | Deadline: 2026-09-18

Buyer: SADEV 94 | Notice type: cn-standard | Procedure: neg-w-call | Contract: services | Deadline: 2026-09-18

Buyer: Ville de Limbourg | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-09-18

Buyer: Agence de Développement de l'Enseignement Technique (ADET) | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-09-18

Buyer: CONSEIL DEPARTEMENTAL DU CALVADOS (CD 14) | Notice type: cn-social | Procedure: open | Contract: services | Deadline: 2026-09-18

Buyer: CNRS Délégation Provence et Corse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-09-18

Buyer: DIREZIONE CENTRALE ACQUISTI | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-09-18

Buyer: Conseil Départemental de l'Ariège (09) | Notice type: cn-standard | Procedure: open | Contract: works | Deadline: 2026-09-18